诺华制药
NVS139.195USD
+0.315+0.23%
收盘 12/26, 16:00（美东）报价延迟15分钟
267.09B总市值
18.90市盈率 TTM
关于 诺华制药 公司
诺华公司为瑞士总部的全球制药巨头，专注创新处方药的研发、制造与行销。公司现以单一 创新药物 部门运营，聚焦免疫、肿瘤、神经、心血管、肾脏及代谢等治疗领域，并运用数字平台加速临床与商业决策。此前属下的仿制药与生物仿制药业务已分拆为独立公司 Sandoz，因此诺华资源得以全面投入先进疗法与下一代技术平台。
诺华制药简介
公司代码NVS
公司名称Novartis AG
上市日期May 07, 2001
CEONarasimhan (Vasant)
员工数量75883
证券类型Depository Receipt
年结日May 07
公司地址Lichtstrasse 35
城市BASEL
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家Switzerland
邮编4056
电话41613241111
网址https://www.novartis.com/
公司代码NVS
上市日期May 07, 2001
CEONarasimhan (Vasant)
诺华制药公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
Mr. Giovanni Caforio, M.D.
Mr. Giovanni Caforio, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Aaron (Ronny) Gal, Ph.D.
Mr. Aaron (Ronny) Gal, Ph.D.
Chief Strategy and Growth Officer, Member of the Executive Committee
Chief Strategy and Growth Officer, Member of the Executive Committee
--
--
Mr. Victor Bulto
Mr. Victor Bulto
President - US, Member of the Executive Committee
President - US, Member of the Executive Committee
--
--
Ms. Charlotte Pamer- Wieser, Ph.D.
Ms. Charlotte Pamer- Wieser, Ph.D.
Corporate Secretary
Corporate Secretary
--
--
Ms. Karen L. Hale
Ms. Karen L. Hale
Chief Legal & Compliance Officer, Member of the Executive Committee
Chief Legal & Compliance Officer, Member of the Executive Committee
--
--
Mr. Frans van Houten
Mr. Frans van Houten
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth Mcnally
Ms. Elizabeth Mcnally
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
Mr. Giovanni Caforio, M.D.
Mr. Giovanni Caforio, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Aaron (Ronny) Gal, Ph.D.
Mr. Aaron (Ronny) Gal, Ph.D.
Chief Strategy and Growth Officer, Member of the Executive Committee
Chief Strategy and Growth Officer, Member of the Executive Committee
--
--
Mr. Victor Bulto
Mr. Victor Bulto
President - US, Member of the Executive Committee
President - US, Member of the Executive Committee
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Rest of portfolio
2.47B
17.58%
Cardiovascular, Renal and Metabolism - Entresto
2.36B
16.77%
Immunology - Cosentyx
1.63B
11.59%
Oncology -Kisqali
1.18B
8.37%
Neuroscience - Kesimpta
1.08B
7.66%
其他
5.34B
38.02%
地区USD
名称
营收
占比
US
6.25B
44.46%
Europe
4.17B
29.67%
Asia / Africa / Australasia
2.71B
19.30%
Canada and Latin America
922.00M
6.56%
业务
地区
业务USD
名称
营收
占比
Rest of portfolio
2.47B
17.58%
Cardiovascular, Renal and Metabolism - Entresto
2.36B
16.77%
Immunology - Cosentyx
1.63B
11.59%
Oncology -Kisqali
1.18B
8.37%
Neuroscience - Kesimpta
1.08B
7.66%
其他
5.34B
38.02%
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Dodge & Cox
0.55%
PRIMECAP Management Company
0.49%
Dimensional Fund Advisors, L.P.
0.46%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.30%
其他
97.83%
持股股东
持股股东
占比
Dodge & Cox
0.55%
PRIMECAP Management Company
0.49%
Dimensional Fund Advisors, L.P.
0.46%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.30%
其他
97.83%
股东类型
持股股东
占比
Investment Advisor
3.41%
Investment Advisor/Hedge Fund
2.86%
Research Firm
0.48%
Hedge Fund
0.20%
Bank and Trust
0.13%
Pension Fund
0.03%
Family Office
0.02%
其他
92.88%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
1967
135.58M
7.06%
-11.39M
2025Q2
1941
140.71M
7.27%
+2.13M
2025Q1
1953
141.07M
7.20%
+870.45K
2024Q4
1926
134.00M
6.78%
-9.24M
2024Q3
1858
134.89M
6.74%
-11.71M
2024Q2
1840
139.20M
6.87%
-9.16M
2024Q1
1808
141.30M
6.92%
-7.93M
2023Q4
1811
141.99M
6.94%
-15.97M
2023Q3
1775
150.92M
7.33%
-7.18M
2023Q2
1759
150.74M
7.28%
-24.15M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Dodge & Cox
10.65M
0.55%
-1.17M
-9.90%
Jun 30, 2025
PRIMECAP Management Company
10.40M
0.54%
+18.55K
+0.18%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
9.06M
0.47%
+454.17K
+5.28%
Jun 30, 2025
Fisher Investments
7.12M
0.37%
+358.28K
+5.30%
Jun 30, 2025
Loomis, Sayles & Company, L.P.
5.58M
0.29%
+78.48K
+1.43%
Jun 30, 2025
Franklin Mutual Advisers, LLC
4.16M
0.21%
-702.88K
-14.45%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
3.65M
0.19%
+129.18K
+3.67%
Jun 30, 2025
Parametric Portfolio Associates LLC
3.08M
0.16%
+80.38K
+2.68%
Jun 30, 2025
Managed Account Advisors LLC
2.92M
0.15%
+7.18K
+0.25%
Jun 30, 2025
Aperio Group, LLC
2.24M
0.12%
+160.56K
+7.71%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
VanEck Pharmaceutical ETF
19.83%
Amplify International Enhanced Dividend Income ETF
3.67%
Abacus FCF International Leaders ETF
3.41%
Altrius Global Dividend ETF
2.39%
Invesco International Dividend Achievers ETF
2.08%
Freedom Day Dividend ETF
2.03%
Fundamentals First ETF
1.91%
SP Funds S&P World (ex-US) ETF
1.56%
DFA Dimensional Internatl High Profitability ETF
1.54%
Avantis Responsible International Equity ETF
1.35%
查看更多
VanEck Pharmaceutical ETF
占比19.83%
Amplify International Enhanced Dividend Income ETF
占比3.67%
Abacus FCF International Leaders ETF
占比3.41%
Altrius Global Dividend ETF
占比2.39%
Invesco International Dividend Achievers ETF
占比2.08%
Freedom Day Dividend ETF
占比2.03%
Fundamentals First ETF
占比1.91%
SP Funds S&P World (ex-US) ETF
占比1.56%
DFA Dimensional Internatl High Profitability ETF
占比1.54%
Avantis Responsible International Equity ETF
占比1.35%
分红派息
近5年累计派现
36.74B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Feb 20, 2025
NVS.NB Final Cash Dividend of gross USD 3.99399 paid on Apr 25, 2025 going ex on Mar 12, 2025
Mar 12, 2025
Apr 25, 2025
Mar 12, 2025
Feb 12, 2024
NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Apr 19, 2024
Mar 07, 2024
Feb 02, 2023
NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 20, 2023
Mar 09, 2023
Feb 04, 2022
NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022
Mar 09, 2022
Mar 17, 2022
Mar 08, 2022
Jan 26, 2021
NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021
Mar 05, 2021
Mar 15, 2021
Mar 04, 2021
Jan 31, 2020
NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020
Mar 04, 2020
Mar 12, 2020
Mar 03, 2020
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
诺华制药的前五大股东是谁？
诺华制药 的前五大股东如下：
Dodge & Cox持有股份：10.65M，占总股份比例：0.55%。
PRIMECAP Management Company持有股份：10.40M，占总股份比例：0.54%。
Dimensional Fund Advisors, L.P.持有股份：9.06M，占总股份比例：0.47%。
Fisher Investments持有股份：7.12M，占总股份比例：0.37%。
Loomis, Sayles & Company, L.P.持有股份：5.58M，占总股份比例：0.29%。
Dodge & Cox持有股份：10.65M，占总股份比例：0.55%。
PRIMECAP Management Company持有股份：10.40M，占总股份比例：0.54%。
Dimensional Fund Advisors, L.P.持有股份：9.06M，占总股份比例：0.47%。
Fisher Investments持有股份：7.12M，占总股份比例：0.37%。
Loomis, Sayles & Company, L.P.持有股份：5.58M，占总股份比例：0.29%。
诺华制药的前三大股东类型是什么？
诺华制药 的前三大股东类型分别是：
Dodge & Cox
PRIMECAP Management Company
Dimensional Fund Advisors, L.P.
Dodge & Cox
PRIMECAP Management Company
Dimensional Fund Advisors, L.P.
有多少机构持有诺华制药(NVS)的股份？
截至2025Q3，共有1967家机构持有诺华制药的股份，合计持有的股份价值约为135.58M，占公司总股份的7.06%。与2025Q2相比，机构持股有所增加，增幅为-0.20%。
哪个业务部门对诺华制药的收入贡献最大？
在FY2025Q2，Rest of portfolio业务部门对诺华制药的收入贡献最大，创收2.47B，占总收入的17.58%。
